Manufacturers submit Marketing Authorisation Application for lonapegsomatropin for paediatric growth hormone deficiency to the European Medicines Agency

Lonapegsomatropin is an investigational long-acting once-weekly prodrug of somatropin (human growth hormone). The submission includes data from eight clinical trials evaluating safety and efficacy in more than 400 subjects with growth hormone deficiency.


Biospace Inc.